Recent Research Analysts’ Ratings Updates for Teva Pharmaceutical Industries (TEVA)

Teva Pharmaceutical Industries (NYSE: TEVA) has recently received a number of price target changes and ratings updates:

  • 12/5/2017 – Teva Pharmaceutical Industries was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 11/29/2017 – Teva Pharmaceutical Industries was given a new $11.00 price target on by analysts at Royal Bank Of Canada. They now have a “sell” rating on the stock.
  • 11/29/2017 – Teva Pharmaceutical Industries had its price target raised by analysts at Mizuho from $12.00 to $16.00. They now have a “neutral” rating on the stock.
  • 11/28/2017 – Teva Pharmaceutical Industries was given a new $16.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
  • 11/27/2017 – Teva Pharmaceutical Industries was given a new $10.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 11/25/2017 – Teva Pharmaceutical Industries had its “hold” rating reaffirmed by analysts at Wells Fargo & Company.
  • 11/17/2017 – Teva Pharmaceutical Industries had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $12.00 price target on the stock, down previously from $15.00.
  • 11/14/2017 – Teva Pharmaceutical Industries was given a new $10.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 11/13/2017 – Teva Pharmaceutical Industries was downgraded by analysts at J P Morgan Chase & Co from a “neutral” rating to an “underweight” rating. They now have a $11.00 price target on the stock, down previously from $11.48.
  • 11/12/2017 – Teva Pharmaceutical Industries had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 11/7/2017 – Teva Pharmaceutical Industries was downgraded by analysts at from a “hold” rating to a “reduce” rating.
  • 11/6/2017 – Teva Pharmaceutical Industries had its price target lowered by analysts at Susquehanna Bancshares Inc from $20.00 to $14.00. They now have a “positive” rating on the stock.
  • 11/6/2017 – Teva Pharmaceutical Industries had its “underperform” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $8.00 price target on the stock, down previously from $14.00.
  • 11/5/2017 – Teva Pharmaceutical Industries had its price target raised by analysts at Royal Bank Of Canada from $8.00 to $13.00. They now have an “underperform” rating on the stock.
  • 11/3/2017 – Teva Pharmaceutical Industries had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $12.00 price target on the stock.
  • 11/3/2017 – Teva Pharmaceutical Industries had its price target lowered by analysts at Morgan Stanley from $14.00 to $7.00. They now have an “underweight” rating on the stock.
  • 11/3/2017 – Teva Pharmaceutical Industries was downgraded by analysts at Deutsche Bank AG from a “buy” rating to a “hold” rating. They now have a $14.00 price target on the stock.
  • 11/2/2017 – Teva Pharmaceutical Industries was downgraded by analysts at Wells Fargo & Company to a “market perform” rating. They now have a $11.36 price target on the stock, down previously from $17.00.
  • 10/30/2017 – Teva Pharmaceutical Industries had its “hold” rating reaffirmed by analysts at Mizuho. They now have a $15.00 price target on the stock.
  • 10/30/2017 – Teva Pharmaceutical Industries had its “underperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $13.00 price target on the stock, down previously from $15.00.
  • 10/26/2017 – Teva Pharmaceutical Industries was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock. They wrote, “Today Mylan (MYL; Neutral) announced the UK High Court of Justice found all claims of Teva’s patent EP ‘355 relating to Copaxone 40mg/mL invalid based on obviousness.””
  • 10/25/2017 – Teva Pharmaceutical Industries was given a new $38.00 price target on by analysts at Evercore ISI. They now have a “buy” rating on the stock.
  • 10/20/2017 – Teva Pharmaceutical Industries was given a new $15.00 price target on by analysts at Royal Bank Of Canada. They now have a “sell” rating on the stock.
  • 10/20/2017 – Teva Pharmaceutical Industries was given a new $19.00 price target on by analysts at Barclays PLC. They now have a “hold” rating on the stock.
  • 10/19/2017 – Teva Pharmaceutical Industries was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 10/13/2017 – Teva Pharmaceutical Industries was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down $0.74 during trading hours on Thursday, hitting $14.32. The stock had a trading volume of 22,053,602 shares, compared to its average volume of 15,674,351. Teva Pharmaceutical Industries Limited has a 52-week low of $10.85 and a 52-week high of $38.31. The stock has a market cap of $15,300.96, a price-to-earnings ratio of 3.48 and a beta of 0.55. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a $0.085 dividend. The ex-dividend date is Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a yield of 2.37%. Teva Pharmaceutical Industries’s payout ratio is currently -12.10%.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.